Person · CIK 1638474

Jeffrey W. Albers

Director at Spyre Therapeutics and Kymera Therapeutics; CEO AND PRESIDENT at Blueprint Medicines

Earlier: Magenta Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$66.9M

Noticed on Form 144$20.8M

Bought on Form 4$0

Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Spyre Therapeutics AGLE	Common Stock	By Sessions LLC	9,360	Aug 7, 2026 · Filing · EDGAR
Spyre Therapeutics AGLE	Stock Option (Right to Buy) exercise $10.39, expires Nov 22, 2033, into Common Stock	Directly	45,000	Aug 7, 2026 · Filing · EDGAR
Kymera Therapeutics KYMR	Stock Option (Right to Buy) exercise $99.87, expires Jun 23, 2036, into Common Stock	Directly	6,068	Jun 24, 2026 · Filing · EDGAR
Magenta Therapeutics	Common Stock	Directly	4,152	Jun 25, 2018 · Filing · EDGAR
Magenta Therapeutics	Stock Option (Right to Buy) exercise $1.21, expires Jun 27, 2032, into Common Stock	Directly	20,000	Jun 28, 2022 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	$2.4M	$2.4M
Q4 2025	$745K	$619K
Q2 2025	$817K	$780K
Q1 2025	$3.3M	$2.2M
Q4 2024	$2.1M	$2.6M
Q3 2024	$1.9M	$1.9M
Q1 2024	$5.7M	$4.7M
Q4 2023	$2.4M	$2.7M
Q3 2023	$2.5M	$3M
Q1 2023	$447K	Not machine-readable
Q4 2022	$1M	Not machine-readable
Q3 2022	$2.8M	Not machine-readable
Q2 2022	$1.5M	Not machine-readable
Q1 2022	$1.9M	Not machine-readable
Q4 2021	$4M	Not machine-readable
Q3 2021	$2.3M	Not machine-readable
Q2 2021	$2.3M	Not machine-readable
Q1 2021	$1.7M	Not machine-readable
Q4 2020	$3.1M	Not machine-readable
Q3 2020	$1.5M	Not machine-readable
Q2 2020	$1.3M	Not machine-readable
Q1 2020	$1.2M	Not machine-readable
Q4 2019	$1.5M	Not machine-readable
Q3 2019	$1.6M	Not machine-readable
Q2 2019	$2.2M	Not machine-readable
Q1 2019	$1.7M	Not machine-readable
Q4 2018	$1.3M	Not machine-readable
Q3 2018	$1.4M	Not machine-readable
Q2 2018	$1.6M	Not machine-readable
Q1 2018	$1.9M	Not machine-readable
Q4 2017	$2.1M	Not machine-readable
Q3 2017	$1.5M	Not machine-readable
Q2 2017	$1M	Not machine-readable
Q1 2017	$801K	Not machine-readable
Q3 2016	$389K	Not machine-readable
Q2 2016	$688K	Not machine-readable
Q4 2015	$363K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Spyre Therapeutics AGLE · Morgan Stanley Smith Barney · 10b5-1 plan adopted Apr 16, 2026 · 2 notices
Aug 7, 2026	5,000 · ~$517K	Aug 7, 2026	Not sold yet	Filing · EDGAR
Aug 7, 2026	18,000 · ~$1.9M	Aug 7, 2026	Partly sold Sold 13,000 in 2 sales, Aug 7 to Aug 7 · $1.4M likely match Form 4	Filing · EDGAR
Kymera Therapeutics KYMR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 21, 2024 · 3 notices
Dec 8, 2025	5,000 · ~$333K	Dec 8, 2025	Sold as noticed Sold 5,000 in 2 sales, Dec 8 to Dec 8 · $449K Form 4	Filing · EDGAR
Oct 13, 2025	5,000 · ~$286K	Oct 13, 2025	Sold as noticed Sold 5,000 at $59.19 on Oct 13 · $296K Form 4	Filing · EDGAR
Jun 3, 2025	6,349 · ~$274K	Jun 3, 2025	Sold as noticed Sold 6,349 at $49.00 on Jun 3 · $311K Form 4	Filing · EDGAR
Blueprint Medicines BPMC · Citigroup Global Markets · 10b5-1 plan adopted May 8, 2024 · 7 notices
May 27, 2025	5,000 · ~$506K	May 27, 2025	Sold as noticed Sold 5,000 in 2 sales, May 27 to May 27 · $506K Form 4	Filing · EDGAR
Jan 21, 2025	15,161 · ~$1.7M	Jan 21, 2025	Partly sold Sold 14,961 in 2 sales, Jan 21 to Jan 21 · $1.6M likely match Form 4	Filing · EDGAR
Jan 14, 2025	5,000 · ~$511K	Jan 13, 2025	Sold as noticed Sold 5,000 at $102.28 on Jan 13 · $511K Form 4	Filing · EDGAR
Dec 19, 2024	15,000 · ~$1.3M	Dec 19, 2024	Partly sold Sold 12,880 in 4 sales, Dec 19 to Mar 12 · $1.2M likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Nov 12, 2024	5,000 · ~$510K	Nov 7, 2024	Partly sold Sold 4,120 in 2 sales, Dec 19 to Jan 21 · $368K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Nov 7, 2024	5,000 · ~$510K	Nov 7, 2024	Sold as noticed Sold 5,000 at $102.00 on Nov 7 · $510K Form 4	Filing · EDGAR
Sep 9, 2024	19,702 · ~$1.7M	Sep 9, 2024	Sold as noticed Sold 19,702 in 2 sales, Sep 9 to Sep 9 · $1.7M Form 4	Filing · EDGAR
Spyre Therapeutics AGLE · Morgan Stanley Smith Barney · 10b5-1 plan adopted Apr 16, 2024 · 1 notice
Oct 25, 2024	7,000 · ~$236K	Oct 25, 2024	Sold as noticed Sold 7,000 in 2 sales, Oct 25 to Nov 6 · $257K Form 4 (1) · Form 4 (2)	Filing · EDGAR
Kymera Therapeutics KYMR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 22, 2023 · 4 notices
Aug 26, 2024	5,000 · ~$239K	Aug 26, 2024	Sold as noticed Sold 5,000 at $49.10 on Aug 26 · $246K Form 4	Filing · EDGAR
Feb 21, 2024	4,385 · ~$167K	Feb 21, 2024	Sold as noticed Sold 4,385 at $39.05 on Feb 21 · $171K Form 4	Filing · EDGAR
Feb 20, 2024	615 · ~$24K	Feb 20, 2024	Sold as noticed Sold 615 at $39.07 on Feb 20 · $24K Form 4	Filing · EDGAR
Jan 23, 2024	10,000 · ~$293K	Jan 23, 2024	Sold as noticed Sold 10,000 at $30.05 on Jan 23 · $300K Form 4	Filing · EDGAR
Blueprint Medicines BPMC · J.P. Morgan Securities · 10b5-1 plan adopted May 26, 2023 · 1 notice
Jan 25, 2024	50,073 · ~$4.2M	Jan 25, 2024	Partly sold Sold 46,996 in 7 sales, Jan 25 to Mar 20 · $4.1M likely match Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Blueprint Medicines BPMC · JP Morgan Securities · 10b5-1 plan adopted May 26, 2023 · 2 notices
Nov 24, 2023	40,000 · ~$2.7M	Nov 24, 2023	Partly sold Sold 39,110 in 7 sales, Nov 24 to Jan 25 · $2.9M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4)	Filing · EDGAR
Aug 24, 2023	60,000 · ~$3M	Aug 24, 2023	Sold as noticed Sold 60,000 in 10 sales, Aug 24 to Nov 3 · $3.1M Form 4 (1) · Form 4 (2) · Form 4 (3)	Filing · EDGAR
Sales without a matching Form 144 · 112 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Spyre Therapeutics (AGLE): Sold 10,000 at $104.68 on Aug 7, 2026 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Blueprint Medicines (BPMC): Sold 5,700 at $87.62 on Mar 12, 2025 · $499K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Blueprint Medicines (BPMC): Sold 5,766 at $88.80 on Mar 5, 2025 · $512K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 319 at $44.27 on Mar 6, 2023 · $14K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 9,474 at $45.72 on Mar 6, 2023 · $433K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 20,000 at $50.09 on Dec 5, 2022 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 662 at $71.30 on Aug 22, 2022 · $47K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,748 at $70.47 on Aug 22, 2022 · $546K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,590 at $70.02 on Aug 19, 2022 · $111K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 293 at $69.52 on Aug 16, 2022 · $20K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 12,477 at $68.62 on Aug 16, 2022 · $856K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,230 at $68.01 on Aug 16, 2022 · $492K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 10,000 at $70.07 on Aug 8, 2022 · $701K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 12,758 at $56.21 on May 16, 2022 · $717K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,342 at $55.63 on May 16, 2022 · $297K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,900 at $54.48 on May 16, 2022 · $104K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,000 at $70.11 on Apr 6, 2022 · $351K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,843 at $56.19 on Mar 7, 2022 · $272K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,400 at $59.43 on Mar 4, 2022 · $83K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,100 at $58.28 on Mar 4, 2022 · $239K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,445 at $57.66 on Mar 4, 2022 · $256K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 10,055 at $56.61 on Mar 4, 2022 · $569K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,862 at $60.28 on Mar 3, 2022 · $474K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 100 at $112.14 on Nov 15, 2021 · $11K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 100 at $113.25 on Nov 15, 2021 · $11K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,894 at $113.92 on Nov 15, 2021 · $899K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 21,906 at $114.73 on Nov 15, 2021 · $2.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,000 at $115.16 on Nov 1, 2021 · $576K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 10,185 at $92.21 on Aug 19, 2021 · $939K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 14,815 at $93.01 on Aug 19, 2021 · $1.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,953 at $91.89 on May 12, 2021 · $271K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 16,383 at $92.62 on May 12, 2021 · $1.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,664 at $93.33 on May 12, 2021 · $529K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 8,417 at $86.61 on Mar 4, 2021 · $729K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 569 at $88.63 on Mar 4, 2021 · $50K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 100 at $86.61 on Mar 4, 2021 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 100 at $89.18 on Mar 4, 2021 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 404 at $90.18 on Mar 4, 2021 · $36K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 3,000 at $90.99 on Mar 4, 2021 · $273K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,296 at $91.78 on Mar 4, 2021 · $486K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,100 at $93.21 on Mar 4, 2021 · $103K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,000 at $119.18 on Dec 14, 2020 · $596K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 6,521 at $97.61 on Nov 16, 2020 · $637K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,483 at $98.13 on Nov 16, 2020 · $440K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,869 at $99.55 on Nov 16, 2020 · $485K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,127 at $100.11 on Nov 16, 2020 · $413K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,000 at $99.17 on Oct 7, 2020 · $496K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 8,597 at $74.60 on Aug 19, 2020 · $641K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 11,403 at $75.34 on Aug 19, 2020 · $859K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 9,568 at $63.93 on May 12, 2020 · $612K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,282 at $64.75 on May 12, 2020 · $277K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 6,150 at $65.77 on May 12, 2020 · $404K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 3,337 at $50.40 on Mar 23, 2020 · $168K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 8,850 at $51.30 on Mar 23, 2020 · $454K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,100 at $52.11 on Mar 23, 2020 · $109K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,936 at $53.54 on Mar 23, 2020 · $104K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 3,293 at $54.62 on Mar 23, 2020 · $180K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 484 at $55.34 on Mar 23, 2020 · $27K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,277 at $51.97 on Mar 9, 2020 · $118K	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,656 at $75.36 on Nov 18, 2019 · $577K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 600 at $76.16 on Nov 18, 2019 · $46K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 11,744 at $74.56 on Nov 8, 2019 · $876K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 12,166 at $81.33 on Aug 19, 2019 · $989K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 6,634 at $82.04 on Aug 19, 2019 · $544K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 300 at $82.85 on Aug 19, 2019 · $25K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 800 at $84.42 on Aug 19, 2019 · $68K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 100 at $85.56 on Aug 19, 2019 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 5,000 at $99.06 on Jun 17, 2019 · $495K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,900 at $82.37 on Jun 12, 2019 · $157K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,050 at $83.81 on Jun 12, 2019 · $339K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,859 at $84.61 on Jun 12, 2019 · $411K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 9,191 at $85.72 on Jun 12, 2019 · $788K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 6,126 at $85.61 on Mar 15, 2019 · $524K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 9,423 at $86.41 on Mar 15, 2019 · $814K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,451 at $87.44 on Mar 15, 2019 · $389K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 100 at $62.66 on Nov 5, 2018 · $6K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 17,300 at $63.30 on Nov 5, 2018 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,500 at $64.18 on Nov 5, 2018 · $96K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,100 at $65.53 on Nov 5, 2018 · $72K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 802 at $68.48 on Aug 6, 2018 · $55K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 800 at $69.64 on Aug 6, 2018 · $56K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 12,219 at $70.48 on Aug 6, 2018 · $861K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 6,179 at $71.22 on Aug 6, 2018 · $440K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 8,320 at $78.56 on May 7, 2018 · $654K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 11,680 at $79.15 on May 7, 2018 · $924K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,300 at $88.17 on Mar 2, 2018 · $115K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,284 at $89.07 on Mar 2, 2018 · $203K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 600 at $90.52 on Mar 2, 2018 · $54K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 4,100 at $91.66 on Mar 2, 2018 · $376K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,900 at $92.76 on Mar 2, 2018 · $176K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 3,794 at $93.89 on Mar 2, 2018 · $356K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 6,022 at $94.79 on Mar 2, 2018 · $571K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,100 at $68.95 on Nov 6, 2017 · $76K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 16,469 at $69.74 on Nov 6, 2017 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,432 at $70.40 on Nov 6, 2017 · $523K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,600 at $71.67 on Nov 6, 2017 · $186K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,999 at $72.91 on Nov 6, 2017 · $146K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 400 at $73.89 on Nov 6, 2017 · $30K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 10,000 at $50.70 on Aug 8, 2017 · $507K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,786 at $48.29 on Aug 7, 2017 · $135K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 17,214 at $49.21 on Aug 7, 2017 · $847K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 2,229 at $49.10 on Jun 28, 2017 · $109K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 10,205 at $50.22 on Jun 28, 2017 · $512K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,566 at $51.21 on Jun 28, 2017 · $387K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 980 at $39.75 on Mar 14, 2017 · $39K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 19,020 at $40.04 on Mar 14, 2017 · $762K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 1,008 at $23.22 on Aug 8, 2016 · $23K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 15,992 at $22.84 on Aug 8, 2016 · $365K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 17,000 at $20.03 on Jun 3, 2016 · $341K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 17,000 at $20.42 on Apr 6, 2016 · $347K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 7,000 at $21.87 on Nov 10, 2015 · $153K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Blueprint Medicines (BPMC): Sold 10,000 at $21.02 on Nov 2, 2015 · $210K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Spyre Therapeutics AGLE Director · filings 2023 to 2026 · sold $2.7M · $2.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 7, 2026	Option or RSU exercised or converted	+5,000	$10.39	$52K	5,000 direct	Filing · EDGAR
Aug 7, 2026	Sale under a 10b5-1 plan	−5,000	$104.47	$522K	0 direct	Filing · EDGAR
Aug 7, 2026	Sale under a 10b5-1 plan	−8,000	$104.38	$835K	19,360 By Sessions LLC	Filing · EDGAR
Aug 7, 2026	Sale under a 10b5-1 plan	−10,000	$104.68	$1M	9,360 By Sessions LLC	Filing · EDGAR
Aug 7, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			45,000 direct	Filing · EDGAR
May 27, 2026	Grant or award from the company Stock Option (Right to Buy)	+8,026			8,026 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Stock Option (Right to Buy)	+25,000			25,000 direct	Filing · EDGAR
Nov 6, 2024	Sale under a 10b5-1 plan	−6,700	$36.76	$246K	27,360 By Sessions LLC	Filing · EDGAR
Oct 25, 2024	Sale under a 10b5-1 plan	−300	$36.43	$11K	34,060 By Sessions LLC	Filing · EDGAR
May 14, 2024	Grant or award from the company Stock Option (Right to Buy)	+11,323			11,323 direct	Filing · EDGAR
Nov 24, 2023	Derivative converted	+34,360			34,360 By Sessions LLC	Filing · EDGAR
Nov 24, 2023	Derivative converted Series A Preferred Stock	−859			0 By Sessions LLC	Filing · EDGAR
Nov 22, 2023	Grant or award from the company Stock Option (Right to Buy)	+50,000			50,000 direct	Filing · EDGAR

Kymera Therapeutics KYMR Director · filings 2020 to 2026 · sold $1.8M · $1.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 24, 2026	Grant or award from the company Stock Option (Right to Buy)	+6,068			6,068 direct	Filing · EDGAR
Dec 8, 2025	Option or RSU exercised or converted	+5,000	$14.18	$71K	5,000 direct	Filing · EDGAR
Dec 8, 2025	Sale under a 10b5-1 plan	−2,748	$89.32	$245K	2,252 direct	Filing · EDGAR
Dec 8, 2025	Sale under a 10b5-1 plan	−2,252	$90.30	$203K	0 direct	Filing · EDGAR
Dec 8, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			7,000 direct	Filing · EDGAR
Oct 13, 2025	Option or RSU exercised or converted	+5,000	$10.34	$52K	5,000 direct	Filing · EDGAR
Oct 13, 2025	Sale under a 10b5-1 plan	−5,000	$59.19	$296K	0 direct	Filing · EDGAR
Oct 13, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			0 direct	Filing · EDGAR
Jun 25, 2025	Grant or award from the company Stock Option (Right to Buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 3, 2025	Option or RSU exercised or converted	+6,349	$10.34	$66K	6,349 direct	Filing · EDGAR
Jun 3, 2025	Sale under a 10b5-1 plan	−6,349	$49.00	$311K	0 direct	Filing · EDGAR
Jun 3, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−6,349			5,000 direct	Filing · EDGAR
Aug 26, 2024	Option or RSU exercised or converted	+5,000	$10.34	$52K	5,000 direct	Filing · EDGAR
Aug 26, 2024	Sale under a 10b5-1 plan	−5,000	$49.10	$246K	0 direct	Filing · EDGAR
Aug 26, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			11,349 direct	Filing · EDGAR
Jun 18, 2024	Grant or award from the company Stock Option (Right to Buy)	+16,000			16,000 direct	Filing · EDGAR
Feb 21, 2024	Option or RSU exercised or converted	+4,385	$10.34	$45K	4,385 direct	Filing · EDGAR
Feb 21, 2024	Sale under a 10b5-1 plan	−4,385	$39.05	$171K	0 direct	Filing · EDGAR
Feb 21, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−4,385			16,349 direct	Filing · EDGAR
Feb 20, 2024	Option or RSU exercised or converted	+615	$10.34	$6K	615 direct	Filing · EDGAR
Feb 20, 2024	Sale under a 10b5-1 plan	−615	$39.07	$24K	0 direct	Filing · EDGAR
Feb 20, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−615			20,734 direct	Filing · EDGAR
Jan 23, 2024	Option or RSU exercised or converted	+10,000	$10.34	$103K	10,000 direct	Filing · EDGAR
Jan 23, 2024	Sale under a 10b5-1 plan	−10,000	$30.05	$300K	0 direct	Filing · EDGAR
Jan 23, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			21,349 direct	Filing · EDGAR
Jun 15, 2023	Grant or award from the company Stock Option (Right to Buy)	+12,000			12,000 direct	Filing · EDGAR
Jun 15, 2022	Grant or award from the company Stock Option (Right to Buy)	+12,000			12,000 direct	Filing · EDGAR
Jun 16, 2021	Grant or award from the company Stock Option (Right to Buy)	+20,063			20,063 direct	Filing · EDGAR
Aug 20, 2020	Grant or award from the company Stock Option (Right to Buy)	+40,127			40,127 direct	Filing · EDGAR

Blueprint Medicines BPMC CEO and president · filings 2015 to 2025 · sold $62.4M · $16.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 17, 2025	Returned to the company	−5,777			144,755 direct	Filing · EDGAR
Jul 17, 2025	Tendered in a change of control	−144,755			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−92,500			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−170,000			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−110,500			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−90,000			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−80,000			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−15,000			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−5,300			0 direct	Filing · EDGAR
Jul 17, 2025	Returned to the company Stock Option (Right to Buy)	−4,570			0 direct	Filing · EDGAR
Jun 18, 2025	Grant or award from the company	+3,902	$128.12	$500K	150,532 direct	Filing · EDGAR
May 27, 2025	Option or RSU exercised or converted	+5,000	$36.05	$180K	151,630 direct	Filing · EDGAR
May 27, 2025	Sale under a 10b5-1 plan	−4,350	$101.02	$439K	147,280 direct	Filing · EDGAR
May 27, 2025	Sale under a 10b5-1 plan	−650	$101.93	$66K	146,630 direct	Filing · EDGAR
May 27, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			92,500 direct	Filing · EDGAR
Mar 12, 2025	Option or RSU exercised or converted	+7,500	$36.05	$270K	159,896 direct	Filing · EDGAR
Mar 12, 2025	Sale under a 10b5-1 plan	−5,700	$87.62	$499K	154,196 direct	Filing · EDGAR
Mar 12, 2025	Sale under a 10b5-1 plan	−1,800	$88.37	$159K	152,396 direct	Filing · EDGAR
Mar 12, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,500			97,500 direct	Filing · EDGAR
Mar 5, 2025	Open-market or private sale	−5,766	$88.80	$512K	146,630 direct	Filing · EDGAR
Jan 21, 2025	Option or RSU exercised or converted	+10,000	$36.05	$361K	167,557 direct	Filing · EDGAR
Jan 21, 2025	Sale under a 10b5-1 plan	−7,561	$109.11	$825K	159,996 direct	Filing · EDGAR
Jan 21, 2025	Sale under a 10b5-1 plan	−7,400	$109.92	$813K	152,596 direct	Filing · EDGAR
Jan 21, 2025	Sale under a 10b5-1 plan	−200	$110.61	$22K	152,396 direct	Filing · EDGAR
Jan 21, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			105,000 direct	Filing · EDGAR
Jan 13, 2025	Option or RSU exercised or converted	+5,000	$36.05	$180K	162,557 direct	Filing · EDGAR
Jan 13, 2025	Sale under a 10b5-1 plan	−5,000	$102.28	$511K	157,557 direct	Filing · EDGAR
Jan 13, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			115,000 direct	Filing · EDGAR
Dec 19, 2024	Option or RSU exercised or converted	+15,000	$36.05	$541K	172,557 direct	Filing · EDGAR
Dec 19, 2024	Sale under a 10b5-1 plan	−3,920	$88.28	$346K	168,637 direct	Filing · EDGAR
Dec 19, 2024	Sale under a 10b5-1 plan	−5,180	$89.01	$461K	163,457 direct	Filing · EDGAR
Dec 19, 2024	Sale under a 10b5-1 plan	−3,800	$91.15	$346K	159,657 direct	Filing · EDGAR
Dec 19, 2024	Sale under a 10b5-1 plan	−2,100	$91.96	$193K	157,557 direct	Filing · EDGAR
Dec 19, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−15,000	$36.05	$541K	120,000 direct	Filing · EDGAR
Nov 7, 2024	Option or RSU exercised or converted	+5,000	$36.05	$180K	162,557 direct	Filing · EDGAR
Nov 7, 2024	Sale under a 10b5-1 plan	−5,000	$102.00	$510K	157,557 direct	Filing · EDGAR
Nov 7, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			135,000 direct	Filing · EDGAR
Sep 9, 2024	Option or RSU exercised or converted	+10,000	$36.05	$361K	177,259 direct	Filing · EDGAR
Sep 9, 2024	Sale under a 10b5-1 plan	−11,968	$85.86	$1M	165,291 direct	Filing · EDGAR
Sep 9, 2024	Sale under a 10b5-1 plan	−7,734	$85.12	$658K	157,557 direct	Filing · EDGAR
Sep 9, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			140,000 direct	Filing · EDGAR
Jun 12, 2024	Grant or award from the company	+2,242			167,259 direct	Filing · EDGAR
Jun 12, 2024	Grant or award from the company Stock Option (Right to Buy)	+4,570			4,570 direct	Filing · EDGAR
Mar 20, 2024	Option or RSU exercised or converted	+15,073	$1.87	$28K	191,123 direct	Filing · EDGAR
Mar 20, 2024	Option or RSU exercised or converted	+10,000	$15.01	$150K	201,123 direct	Filing · EDGAR
Mar 20, 2024	Sale under a 10b5-1 plan	−2,730	$85.22	$233K	198,393 direct	Filing · EDGAR
Mar 20, 2024	Sale under a 10b5-1 plan	−6,251	$86.46	$540K	192,142 direct	Filing · EDGAR
Mar 20, 2024	Sale under a 10b5-1 plan	−8,440	$87.26	$736K	183,702 direct	Filing · EDGAR
Mar 20, 2024	Sale under a 10b5-1 plan	−6,285	$88.60	$557K	177,417 direct	Filing · EDGAR
Mar 20, 2024	Sale under a 10b5-1 plan	−1,367	$89.12	$122K	176,050 direct	Filing · EDGAR
Mar 20, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−15,073			0 direct	Filing · EDGAR
Mar 20, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Mar 7, 2024	Open-market or private sale	−11,033	$90.69	$1M	165,017 direct	Filing · EDGAR
Jan 25, 2024	Option or RSU exercised or converted	+15,000	$1.87	$28K	191,050 direct	Filing · EDGAR
Jan 25, 2024	Option or RSU exercised or converted	+10,000	$15.01	$150K	201,050 direct	Filing · EDGAR
Jan 25, 2024	Sale under a 10b5-1 plan	−6,086	$81.16	$494K	194,964 direct	Filing · EDGAR
Jan 25, 2024	Sale under a 10b5-1 plan	−10,890	$81.70	$890K	184,074 direct	Filing · EDGAR
Jan 25, 2024	Sale under a 10b5-1 plan	−7,924	$82.76	$656K	176,150 direct	Filing · EDGAR
Jan 25, 2024	Sale under a 10b5-1 plan	−100	$83.57	$8K	176,050 direct	Filing · EDGAR
Jan 25, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−15,000			15,073 direct	Filing · EDGAR

243 earlier transactions are in the filing list below.

Magenta Therapeutics Director · filings 2018 to 2022

Date	Transaction	Shares	Held after	Source
Jun 28, 2022	Grant or award from the company Stock Option (Right to Buy)	+20,000	20,000 direct	Filing · EDGAR
Jun 1, 2021	Grant or award from the company Stock Option (Right to Buy)	+18,188	18,188 direct	Filing · EDGAR
Jun 5, 2020	Grant or award from the company Stock Option (Right to Buy)	+18,188	18,188 direct	Filing · EDGAR
Jun 7, 2019	Grant or award from the company Stock Option (Right to Buy)	+18,188	18,188 direct	Filing · EDGAR
Jun 25, 2018	Derivative converted	+4,152	4,152 direct	Filing · EDGAR
Jun 25, 2018	Derivative converted Series C Preferred Stock	−10,729	0 direct	Filing · EDGAR

All 120 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Aug 10, 2026	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
Aug 7, 2026	Form 144	Spyre Therapeutics AGLE	Filing · EDGAR
Aug 7, 2026	Form 144	Spyre Therapeutics AGLE	Filing · EDGAR
Jun 25, 2026	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
May 29, 2026	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
Dec 8, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 8, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Oct 14, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Oct 14, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jul 21, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 26, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 24, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 3, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 3, 2025	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 2, 2025	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
May 29, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
May 27, 2025	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Mar 17, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 14, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jan 23, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jan 21, 2025	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Jan 15, 2025	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jan 14, 2025	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Dec 20, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Dec 19, 2024	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Nov 12, 2024	Form 144/A	Blueprint Medicines BPMC	Filing · EDGAR
Nov 12, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 8, 2024	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
Nov 7, 2024	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Oct 28, 2024	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
Oct 25, 2024	Form 144	Spyre Therapeutics AGLE	Filing · EDGAR
Sep 11, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Sep 9, 2024	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Aug 26, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Aug 26, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 20, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 14, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
May 16, 2024	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
Mar 26, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 22, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Feb 21, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Feb 21, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Feb 20, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jan 29, 2024	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jan 25, 2024	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Jan 23, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jan 23, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 13, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Dec 8, 2023	Form 4/A	Spyre Therapeutics AGLE	Filing · EDGAR
Dec 8, 2023	Form 3/A	Spyre Therapeutics AGLE	Filing · EDGAR
Dec 4, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 28, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 27, 2023	Form 4	Spyre Therapeutics AGLE	Filing · EDGAR
Nov 27, 2023	Form 3	Spyre Therapeutics AGLE	Filing · EDGAR
Nov 24, 2023	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Nov 3, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Sep 29, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 28, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 24, 2023	Form 144	Blueprint Medicines BPMC	Filing · EDGAR
Jun 23, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 20, 2023	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 8, 2023	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Dec 7, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 23, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 18, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 10, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 30, 2022	Form 4	Magenta Therapeutics	Filing · EDGAR
Jun 16, 2022	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
May 18, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Apr 8, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 8, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 3, 2022	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 17, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 3, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 30, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 23, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 17, 2021	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 3, 2021	Form 4	Magenta Therapeutics	Filing · EDGAR
May 14, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 5, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 3, 2021	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Dec 16, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 18, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Oct 9, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 21, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 21, 2020	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Aug 20, 2020	Form 3	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 9, 2020	Form 4	Magenta Therapeutics	Filing · EDGAR
May 14, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 25, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 11, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 3, 2020	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 20, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Oct 30, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 21, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 19, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 14, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 11, 2019	Form 4	Magenta Therapeutics	Filing · EDGAR
Mar 19, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 5, 2019	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 21, 2018	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 7, 2018	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 8, 2018	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 27, 2018	Form 4	Magenta Therapeutics	Filing · EDGAR
Jun 20, 2018	Form 3	Magenta Therapeutics	Filing · EDGAR
May 9, 2018	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 6, 2018	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Feb 20, 2018	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 8, 2017	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 9, 2017	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 30, 2017	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Mar 16, 2017	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Feb 21, 2017	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Aug 10, 2016	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Jun 7, 2016	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Apr 8, 2016	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Feb 5, 2016	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 12, 2015	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Nov 4, 2015	Form 4	Blueprint Medicines BPMC	Filing · EDGAR
Apr 30, 2015	Form 3	Blueprint Medicines BPMC	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.